Medtronic’s Evolut trial outcome could shift US TAVR market
Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...
Express Healthcare1d
Medtronic’s Evolut trial outcome could alter US TAVR market: GlobalData
The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...
Yahoo Finance1d
Medtronic’s Evolut trial outcome could shift US TAVR market
Medtronic has released the two-year results from the clinical trial comparing its Evolut system to Edwards Lifesciences’ SAPIEN system. The Evolut system showed significantly less bioprosthetic ...
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...
Medscape2d
Better 5-Year Valve Performance With TAVI Than Surgery
Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...
FDA issues Medtronic embolization device recall and correction notice
In a notice posted to the agency’s website, the FDA noted that on January 30, 2025, Medtronic (MDT) Neurovascular sent all affected customers ...
ahajournals.org4d
Cost-Effectiveness of Aortic Valve Replacement in Low- and Intermediate-Risk Chinese Patients With Severe Aortic Stenosis
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, China. (J.P., M.J., X.Y., Y.M., M.F., Y.F.) Center for ...
American College of Cardiology5d
Section Announcements
ACC's new online course, Baroreflex Activation Therapy: Optimizing Treatment of HF, covers the stages of heart failure (HF) where baroreflex activation therapy (BAT) is effective, including its ...